放射性核素显像在帕金森病鉴别诊断中的应用

邓玮玮; 张春银; 邓玮玮; 张春银

doi:10.3760/cma.j.issn.1673-4114.2017.02.010

[1]

Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease:Clinicopathologic study[J]. Neurology, 2014, 83(5):406-412. DOI:10. 1212/WNL. 0000000000000641.

[2]

Holtbernd F, Eidelberg D. The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes[J]. Semin Neurol, 2014, 34(2):202-209. DOI:10. 1055/s-0034-1381733.

[3]

Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease[J]. Clin Med(Lond), 2016, 16(4):371-375. DOI:10.7861/clinmedicine. 16-4-371.

[4]

Sarikaya I. PET imaging in neurology:Alzheimer's and Parkinson's diseases[J]. Nucl Med Commun, 2015, 36(8):775-781. DOI:10. 1097/mnm. 0000000000000320.

[5]

Picco A, Morbelli S, Piccardo A, et al. Brain ¹⁸F-DOPA PET and cognition in de novo Parkinson's disease[J]. Eur J Nucl Med Mol Imaging, 2015, 42(7):1062-1070. DOI:10. 1007/s00259-015-3039-0.

[6]

Otsuka M, Ichiya Y, Hosokawa S, et al. Striatal blood flow, glucose metabolism and ¹⁸F-dopa uptake:difference in Parkinson's disease and atypical parkinsonism[J]. J Neurol Neurosurg Psychiatry, 1991, 54(10):898-904. DOI:10. 1136/jnnp.54.10.898.

[7]

Calabria FF, Calabria E, Gangemi V, et al. Current status and future challenges of brain imaging with ¹⁸F-DOPA PET for movement disorders[J]. Hell J Nucl Med, 2016, 19(1):33-41. DOI:10.1967/s002449910335.

[8]

Jaimini A, Tripathi M, D'Souza MM, et al. Utility of intrastriatal ratios of FDOPA to differentiate idiopathic Parkinson's disease from atypical parkinsonian disorders[J]. Nucl Med Commun, 2013, 34(5):426-431. DOI:10.1097/MNM. 0b013e32835fcd7f.

[9]

Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of[I-123] -FP-CIT SPECT imaging:the[I-123] -FP-CIT study group[J]. Mov Disord, 2000, 15(3):503-510. doi: 10.1002/1531-8257(200005)15:3<>1.0.CO;2-5

[10]

Vlaar AM, van Kroonenburgh MJ, Kessels AG, et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes[J]. BMC Neurol, 2007, 7:27. DOI:10.1186/1471-2377-7-27.

[11]

Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of ¹²³I-ioflupane and ¹²³I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes[J]. Eur Neurol, 2008, 59(5):258-266. DOI:10.1159/000115640.

[12]

Lorberboym M, Treves TA, Melamed E, et al.[¹²³I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease[J]. Mov Disord, 2006, 21(4):510-514. DOI:10.1002/mds.20748.

[13]

Messa C, Volonté MA, Fazio F, et al. Differential distribution of striatal[¹²³I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography[J]. Eur J Nucl Med, 1998, 25(9):1270-1276. DOI:10.1007/s002590050295.

[14]

Plotkin M, Amthauer H, Klaffke S, et al. Combined ¹²³I-FP-CIT and ¹²³I-IBZM SPECT for the diagnosis of parkinsonian syndromes:study on 72 patients[J]. J Neural Transm(Vienna), 2005, 112(5):677-692. DOI:10.1007/s00702-004-0208-x.

[15]

Nocker M, Seppi K, Donnemiller E, et al. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy:a voxel-based analysis of[¹²³I]β-CIT SPECT[J]. Eur J Nucl Med Mol Imaging, 2012, 39(6):1012-1020. DOI:10.1007/s00259-012-2100-5.

[16]

Brigo F, Matinella A, Erro R, et al.[¹²³I]FP-CIT SPECT(DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms:a meta-analysis[J]. Eur J Neurol, 2014, 21(11):1369-1390. DOI:10.1111/ene.12444.

[17]

Van Laere K, Clerinx K, D'hondt E, et al. Combined striatal binding and cerebral influx analysis of dynamic ¹¹C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease[J]. J Nucl Med, 2010, 51(4):588-595. DOI:10.2967/jnumed.109.070144.

[18]

Tatsch K, Schwarz J, Oertel WH, et al. SPECT imaging of dopamine D2 receptors with ¹²³I-IBZM:initial experience in controls and patients with Parkinson's syndrome and Wilson's disease[J]. Nucl Med Commun, 1991, 12(8):699-707. DOI:10.1097/00006231-199108000-00005.

[19]

Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism:a multidimensional statistical approach[J]. J Nucl Med, 2011, 52(5):733-740. DOI:10.2967/jnumed.110.086959.

[20]

Hellwig S, Amtage F, Kreft A, et al.[¹⁸F]FDG-PET is superior to[¹²⁵I]IBZM-SPECT for the differential diagnosis of parkinsonism[J]. Neurology, 2012, 79(13):1314-1322. DOI:10.1212/WNL.0b013e31826c1b0a.

[21]

Koch W, Hamann C, Radau PE, et al. Does combined imaging of the pre-and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?[J]. Eur J Nucl Med Mol Imaging, 2007, 34(8):1265-1273. DOI:10.1007/s00259-007-0375-8.

[22]

Ishibashi K, Nishina H, Ishiwata K, et al. Individual time course of pre-and postsynaptic PET imaging may improve differential diagnosis of Parkinson's disease and multiple system atrophy:a case report[J]. BMC Res Notes, 2015, 8:496. DOI:10.1186/s13104-015-1522-0.

[23]

Juh R, Kim J, Moon D, et al. Different metabolic patterns analysis of Parkinsonism on the ¹⁸F-FDG PET[J]. Eur J Radiol, 2004, 51(3):223-233. DOI:10.1016/S0720-048X(03)00214-6.

[24]

Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with ¹⁸F-fluorodeoxyglucose and positron emission tomography[J]. Neurology, 1995, 45(11):1995-2004. DOI:10.1212/WNL.45.11.1995.

[25]

Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism:a metabolic imaging study using pattern analysis[J]. Lancet Neurol, 2010, 9(2):149-158. DOI:10.1016/S1474-4422(10)70002-8.

[26]

Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks:a validation study[J]. J Nucl Med, 2016, 57(1):60-66. DOI:10.2967/jnumed.115.161992.

[27]

Orimo S, Suzuki M, Inaba A, et al. ¹²³I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism:a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2012, 18(5):494-500. DOI:10.1016/j.parkreldis.2012.01.009.

[28]

Rascol O, Schelosky L. ¹²³I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders[J]. Mov Disord, 2009, Suppl 2:S732-741. DOI:10.1002/mds.22499.

[29]

Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2005, 76(2):249-251. DOI:10.1136/jnnp.2004.037028.